Sclerodermatous chronic GVHD in patients receiving tyrosine kinase inhibitors after allogeneic hematopoietic cell transplantation.
作者信息
Salhotra A, Tsai N, Thomas S H, Paris T, Parker P, Forman S J, Nakamura R
机构信息
Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA.
Department of Biostatistics, City of Hope, Duarte, CA, USA.
出版信息
Bone Marrow Transplant. 2015 Jan;50(1):139-41. doi: 10.1038/bmt.2014.210. Epub 2014 Sep 29.
Abstract
摘要
相似文献
1
Sclerodermatous chronic GVHD in patients receiving tyrosine kinase inhibitors after allogeneic hematopoietic cell transplantation.异基因造血细胞移植后接受酪氨酸激酶抑制剂治疗的患者中的硬皮病样慢性移植物抗宿主病
Bone Marrow Transplant. 2015 Jan;50(1):139-41. doi: 10.1038/bmt.2014.210. Epub 2014 Sep 29.
2
3
Mesenchymal stem cells enhance the impact of KIR receptor-ligand mismatching on acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia but not in those with acute lymphocytic leukemia.间充质干细胞增强了 KIR 受体-配体错配对急性髓系白血病患者异基因造血干细胞移植后急性移植物抗宿主病的影响，但对急性淋巴细胞白血病患者没有影响。
Hematol Oncol. 2021 Aug;39(3):380-389. doi: 10.1002/hon.2867. Epub 2021 Apr 13.
4
Allogeneic Stem Cell Transplantation versus Tyrosine Kinase Inhibitors Combined with Chemotherapy in Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.异基因造血干细胞移植与酪氨酸激酶抑制剂联合化疗治疗费城染色体阳性急性淋巴细胞白血病。
Biol Blood Marrow Transplant. 2018 Apr;24(4):741-750. doi: 10.1016/j.bbmt.2017.12.777. Epub 2017 Dec 13.
5
Pre-engraftment graft-versus-host disease after allogeneic hematopoietic cell transplantation for acute leukemia.异基因造血细胞移植治疗急性白血病后的植入前移植物抗宿主病。
Eur J Haematol. 2011 Aug;87(2):172-81. doi: 10.1111/j.1600-0609.2011.01646.x.
6
7
Prognostic factors on graft-versus-host disease-free and relapse-free survival after allogeneic hematopoietic stem cell transplantation for adults with acute leukemia.成人急性白血病异基因造血干细胞移植后无移植物抗宿主病和无复发生存的预后因素
Leuk Res. 2017 Aug;59:1-7. doi: 10.1016/j.leukres.2017.05.011. Epub 2017 May 12.
8
Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia.酪氨酸激酶抑制剂可改善费城染色体阳性成人急性淋巴细胞白血病患者异基因造血干细胞移植的长期疗效。
Haematologica. 2015 Mar;100(3):392-9. doi: 10.3324/haematol.2014.116954. Epub 2014 Dec 19.
9
Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-versus-host disease.首次完全缓解期进行异基因干细胞移植可增强成人急性淋巴细胞白血病患者的移植物抗白血病效应：慢性移植物抗宿主病的抗白血病活性
Biol Blood Marrow Transplant. 2007 Sep;13(9):1083-94. doi: 10.1016/j.bbmt.2007.06.001. Epub 2007 Jul 20.
10
Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results.氯法拉滨联合白消安是急性淋巴细胞白血病患者异基因造血干细胞移植的有效预处理方案：长期研究结果
Biol Blood Marrow Transplant. 2017 Feb;23(2):285-292. doi: 10.1016/j.bbmt.2016.11.001. Epub 2016 Nov 2.
引用本文的文献
1
BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?BCR-ABL酪氨酸激酶抑制剂：哪种机制可能解释血栓形成风险？
TH Open. 2018 Feb 14;2(1):e68-e88. doi: 10.1055/s-0038-1624566. eCollection 2018 Jan.
本文引用的文献
1
Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD.39 例接受伊马替尼治疗的激素难治性慢性移植物抗宿主病患者的 NIH 反应标准的长期结果和前瞻性验证。
Blood. 2013 Dec 12;122(25):4111-8. doi: 10.1182/blood-2013-05-494278. Epub 2013 Oct 23.
2
Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease.慢性移植物抗宿主病患者硬化的发生率、风险因素和结局。
Blood. 2013 Jun 20;121(25):5098-103. doi: 10.1182/blood-2012-10-464198. Epub 2013 Apr 1.
3
Dasatinib as salvage therapy for steroid refractory and imatinib resistant or intolerant sclerotic chronic graft-versus-host disease.达沙替尼作为挽救治疗用于激素难治性和伊马替尼耐药或不耐受的硬化性慢性移植物抗宿主病。
Biol Blood Marrow Transplant. 2012 Feb;18(2):318-23. doi: 10.1016/j.bbmt.2011.10.042. Epub 2011 Nov 7.
4
A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies.一项伊马替尼治疗糖皮质激素依赖/难治性慢性移植物抗宿主病的 1 期研究：反应与抗 PDGFRA 抗体无关。
Blood. 2011 Oct 13;118(15):4070-8. doi: 10.1182/blood-2011-03-341693. Epub 2011 Aug 9.
5
Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease.硬化型皮肤慢性移植物抗宿主病：临床危险因素、实验室标志物和疾病负担。
Blood. 2011 Oct 13;118(15):4250-7. doi: 10.1182/blood-2011-04-350249. Epub 2011 Jul 26.
6
Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease.甲磺酸伊马替尼作为难治性硬化型慢性移植物抗宿主病的挽救治疗
Blood. 2009 Jul 16;114(3):719-22. doi: 10.1182/blood-2009-02-204750. Epub 2009 Mar 16.
7
Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis.甲磺酸伊马替尼可减少细胞外基质的产生，并预防实验性皮肤纤维化的发展。
Arthritis Rheum. 2007 Jan;56(1):311-22. doi: 10.1002/art.22314.
8
9
Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry.异基因骨髓移植后的长期生存与晚期死亡。国际骨髓移植登记处迟发效应工作委员会。
N Engl J Med. 1999 Jul 1;341(1):14-21. doi: 10.1056/NEJM199907013410103.
10
Sjögren-type syndrome after allogeneic bone-marrow transplantation.
Ann Intern Med. 1977 Dec;87(6):703-6. doi: 10.7326/0003-4819-87-6-703.
Zotero 插件